Doxifluridine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Doxifluridine
Accession Number
DB12947
Description

Doxifluridine has been investigated for the treatment of Stomach Cancer.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 246.1924
Monoisotopic: 246.065199677
Chemical Formula
C9H11FN2O5
Synonyms
  • 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
  • 5-fluoro-5'-deoxyuridine
  • 5'-deoxy-5-fluorouridine
  • 5'-DFUR
  • Doxifluridina
  • Doxifluridine
  • Doxifluridinum
External IDs
  • RO 21-9738
  • RO 219738
  • RO-219738

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Doxifluridine.
AcenocoumarolThe risk or severity of bleeding can be increased when Doxifluridine is combined with Acenocoumarol.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Doxifluridine.
Adenovirus type 7 vaccine liveThe risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Doxifluridine.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Doxifluridine.
AlefaceptThe risk or severity of adverse effects can be increased when Alefacept is combined with Doxifluridine.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Doxifluridine.
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Doxifluridine.
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Doxifluridine.
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Doxifluridine.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
International/Other Brands
Flutron / Furtulon

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 5'-deoxyribonucleosides. These are nucleosides in which the oxygen atom at the 5'position of the ribose moiety has been replaced by another atom. The nucleobases here are limited to purine, pyrimidine, and pyridine derivatives.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
5'-deoxyribonucleosides
Sub Class
Not Available
Direct Parent
5'-deoxyribonucleosides
Alternative Parents
Glycosylamines / Pyrimidones / Halopyrimidines / Aryl fluorides / Hydropyrimidines / Vinylogous amides / Tetrahydrofurans / Heteroaromatic compounds / Ureas / Secondary alcohols
show 9 more
Substituents
1,2-diol / 5'-deoxyribonucleoside / Alcohol / Aromatic heteromonocyclic compound / Aryl fluoride / Aryl halide / Azacycle / Glycosyl compound / Halopyrimidine / Heteroaromatic compound
show 20 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, pyrimidine 5'-deoxyribonucleoside (CHEBI:31521)

Chemical Identifiers

UNII
V1JK16Y2JP
CAS number
3094-09-5
InChI Key
ZWAOHEXOSAUJHY-ZIYNGMLESA-N
InChI
InChI=1S/C9H11FN2O5/c1-3-5(13)6(14)8(17-3)12-2-4(10)7(15)11-9(12)16/h2-3,5-6,8,13-14H,1H3,(H,11,15,16)/t3-,5-,6-,8-/m1/s1
IUPAC Name
1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-1,2,3,4-tetrahydropyrimidine-2,4-dione
SMILES
C[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=C(F)C(=O)NC1=O

References

General References
Not Available
Human Metabolome Database
HMDB0060406
KEGG Drug
D01309
KEGG Compound
C12739
PubChem Compound
18343
PubChem Substance
347829090
ChemSpider
17322
BindingDB
50132295
ChEBI
31521
ChEMBL
CHEMBL1130
ZINC
ZINC000001319177
Wikipedia
Doxifluridine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedSupportive CareMalignant Neoplasm of Stomach1
3CompletedTreatmentMalignant Neoplasm of Stomach2
1CompletedTreatmentLiver Cancer / Metastatic Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility37.7 mg/mLALOGPS
logP-0.77ALOGPS
logP-1.2ChemAxon
logS-0.81ALOGPS
pKa (Strongest Acidic)8.07ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area99.1 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity51.22 m3·mol-1ChemAxon
Polarizability20.99 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 21, 2016 01:32 / Updated on February 21, 2021 18:54